Parse Biosciences, a leading provider of accessible and scalable single-cell sequencing solutions, today announced the availability of Evercode™ TCR and Gene Capture. These new solutions expand Parse Biosciences' portfolio to address larger-scale and immune profiling applications.

"Parse's technology has already brought unprecedented scale to the market and these new tools will extend these capabilities, enabling new applications in both research and transfer."

Evercode TCR offers researchers the ability to profile T-cell receptors (TCRs) with entire transcriptomes into individual cells on a large scale. The diversity of possible TCRs in the immune repertoire is enormous, but the low throughput of existing tools has so far limited the ability to capture this complexity in high resolution. Evercode TCR will allow researchers to measure whole transcriptomes and paired sequences of TCR, both alpha and beta chains, in up to 1 million cells. The combination of TCR sequences with gene expression at this scale makes it possible to track TCR clonotypes across different T cell subtypes and activation states to understand the immune repertoire at exceptional resolution.

Parse also announced the launch of Gene Capture, a solution to reduce sequencing requirements for larger studies. Gene Capture focuses on sequencing the most relevant genes, allowing projects to be efficiently scaled to millions of cells and hundreds of samples. The solution allows researchers to enrich hundreds to thousands of genes, requiring 10 times less sequencing. Researchers can order a predefined panel of about 1,000 immunology-relevant genes, the Immune1000, or design a single panel based on their needs.

"We are increasingly seeing the need to support larger single-cell RNA sequencing studies. Biology is complex and requires robust studies on multiple samples, at different times and with many individual cells to fully grasp this complexity," notes Alex Rosenberg, co-founder and CEO of Parse. "Parse's technology has already brought unprecedented scale to the market and these new tools will extend these capabilities, enabling new applications in both research and transfer."